STAT6 Links IL‐4/IL‐13 Stimulation With Pendrin Expression in Asthma and Chronic Obstructive Pulmonary Disease

Signaling through the interleukin‐4/interleukin‐13 (IL‐4/IL‐13) receptor complex is a crucial mechanism in the development of bronchial asthma and chronic obstructive pulmonary disease (COPD). In bronchial epithelial cells, this signaling pathway leads to changes in the expression levels of several genes that are possibly involved in protection against and/or pathogenesis of these diseases. The expression of pendrin (SLC26A4), a candidate for the latter category, is upregulated by IL‐4/IL‐13 and leads to overproduction of mucus and increased viscosity of the airway surface liquid (ASL). Therefore, elucidating the transcriptional regulation of pendrin could aid in the development of new pharmacological leads for asthma and/or COPD therapy. Here we show that IL‐4/IL‐13 significantly increased human pendrin promoter activity in HEK‐Blue cells but not in STAT6‐deficient HEK293 Phoenix cells; that mutation of the STAT6 binding site (N4 GAS motif) rendered the promoter insensitive to IL‐4/IL‐13; and that addition of the N4 GAS motif to an IL‐4/IL‐13‐unresponsive sequence of the human pendrin promoter conferred sensitivity to both ILs.

[1]  U. Schindler,et al.  Requirements for interleukin-4-induced gene expression and functional characterization of Stat6 , 1996, Molecular and cellular biology.

[2]  R. Ravazzolo,et al.  Effect of inflammatory stimuli on airway ion transport. , 2004, Proceedings of the American Thoracic Society.

[3]  V. Pendred.  DEAF-MUTISM AND GOITRE. , 1896 .

[4]  Jennifer A. Lockridge,et al.  Identification of small interfering RNA targeting Signal Transducer and Activator of Transcription 6: Characterisation and selection of candidates for pre-clinical development , 2010, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

[5]  M. Woisetschläger,et al.  STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts. , 2001, Journal of immunology.

[6]  M. Ariizumi,et al.  Elevated interleukin-4 and interleukin-6 in rats sensitized with toluene diisocyanate. , 2001, Industrial health.

[7]  J. Foidart,et al.  New asthma biomarkers: lessons from murine models of acute and chronic asthma. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[8]  M. Woisetschläger,et al.  Activation of Eotaxin-3/CCL26 Gene Expression in Human Dermal Fibroblasts Is Mediated by STAT6 , 2001, The Journal of Immunology.

[9]  Rong Wang,et al.  The Pendred syndrome gene encodes a chloride-iodide transport protein , 1999, Nature Genetics.

[10]  Goldstein Ra,et al.  NIH conference. Asthma. , 1994 .

[11]  S. Alsowaidi,et al.  Serum Interleukin-13 Levels Are Elevated In Mild And Moderate Persistent Asthma , 2004 .

[12]  E. Green,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Pendrin, the Protein Encoded by the Pendred Syndrome , 1999 .

[13]  Markus Ritter,et al.  Functional Characterization of Wild-Type and a Mutated Form of SLC26A4 Identified in a Patient with Pendred Syndrome , 2006, Cellular Physiology and Biochemistry.

[14]  P. Bucher,et al.  DNA Binding Specificity of Different STAT Proteins , 2001, The Journal of Biological Chemistry.

[15]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[16]  E. Fixman,et al.  Cell-penetrating peptides and proteins: new inhibitors of allergic airways disease. , 2008, Canadian journal of physiology and pharmacology.

[17]  Y. Rhee,et al.  Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. , 2001, The Journal of asthma : official journal of the Association for the Care of Asthma.

[18]  S. Holgate.  A look at the pathogenesis of asthma: the need for a change in direction. , 2010, Discovery medicine.

[19]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[20]  H. Mikawa,et al.  Serum levels of interleukin 4 and soluble CD23 in children with allergic disorders , 1995, European Journal of Pediatrics.

[21]  G. Hershey.  IL-13 receptors and signaling pathways: an evolving web. , 2003, The Journal of allergy and clinical immunology.

[22]  M. Woisetschläger,et al.  STAT6 Mediates Eotaxin-1 Expression in IL-4 or TNF-α-Induced Fibroblasts , 2001, The Journal of Immunology.

[23]  Y. Nakanishi,et al.  Niflumic acid suppresses interleukin-13-induced asthma phenotypes. , 2006, American journal of respiratory and critical care medicine.

[24]  C. Nofziger,et al.  Functional characterization of wild-type and mutated pendrin (SLC26A4), the anion transporter involved in Pendred syndrome. , 2009, Journal of molecular endocrinology.

[25]  P. Kopp,et al.  Pendred syndrome and iodide transport in the thyroid , 2008, Trends in Endocrinology & Metabolism.

[26]  S. McKnight,et al.  Components of a Stat recognition code: evidence for two layers of molecular selectivity. , 1995, Immunity.

[27]  E. Green,et al.  Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome. , 2001, Human molecular genetics.

[28]  H. Danahay,et al.  Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[29]  Y. Chiba,et al.  A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. , 2009, American journal of respiratory cell and molecular biology.

[30]  E. Fixman,et al.  Inhibition of Experimental Allergic Airways Disease by Local Application of a Cell-Penetrating Dominant-Negative STAT-6 Peptide1 , 2007, The Journal of Immunology.

[31]  V. Sheffield,et al.  Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS) , 1997, Nature Genetics.

[32]  R. Ravazzolo,et al.  IL-4 Is a Potent Modulator of Ion Transport in the Human Bronchial Epithelium In Vitro1 , 2002, The Journal of Immunology.

[33]  H. Lee,et al.  Serum Levels of Interleukins (IL)-4, IL-5, IL-13, and Interferon-γ in Acute Asthma , 2001 .

[34]  Carol E. Jones,et al.  Regulation of mucin expression in respiratory diseases. , 2009, Biochemical Society transactions.

[35]  A. Manichaikul,et al.  Do mutations of the Pendred syndrome gene, SLC26A4, confer resistance to asthma and hypertension? , 2009, Journal of Medical Genetics.

[36]  M. Matsuzaki,et al.  Serum levels of soluble IL-2R, IL-4, and soluble Fc epsilon RII in adult bronchial asthma. , 1994, Chest.

[37]  New asthma biomarkers: lessons from murine models of acute and chronic asthma. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[38]  D. Postma,et al.  Elevated serum interferon-gamma in atopic asthma correlates with increased airways responsiveness and circadian peak expiratory flow variation. , 1998, The European respiratory journal.

[39]  N. Jarjour,et al.  Pathogenesis of asthma. , 2002, The Medical clinics of North America.

[40]  P. Howarth,et al.  Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. , 2001, The Journal of allergy and clinical immunology.

[41]  Felipe Moreno,et al.  Functional assessment of allelic variants in the SLC26A4 gene involved in Pendred syndrome and nonsyndromic EVA , 2008, Proceedings of the National Academy of Sciences.

[42]  R. Pauwels.  The relationship between airway inflammation and bronchial hyperresponsiveness , 1989, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[43]  P. Barnes.  New therapies for asthma: is there any progress? , 2010, Trends in pharmacological sciences.

[44]  S. Filetti,et al.  Na(+)/I(-) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. , 2001, European journal of endocrinology.

[45]  E. Green,et al.  Pendrin, encoded by the Pendred syndrome gene, resides in the apical region of renal intercalated cells and mediates bicarbonate secretion , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Matsuzaki,et al.  Serum Levels of Soluble IL-2R, IL-4, and Soluble FcɛRII in Adult Bronchial Asthma , 1994 .

[47]  Y. Zhou,et al.  Characterization of a calcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma. , 2001, American journal of respiratory cell and molecular biology.

[48]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[49]  H. Boushey,et al.  The Epithelial Anion Transporter Pendrin Is Induced by Allergy and Rhinovirus Infection, Regulates Airway Surface Liquid, and Increases Airway Reactivity and Inflammation in an Asthma Model1 , 2008, The Journal of Immunology.

[50]  中尾 功.  Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease , 2008 .

[51]  Yee Hwa Yang,et al.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.

[52]  M. Romero,et al.  The SLC26 gene family of multifunctional anion exchangers , 2004, Pflügers Archiv.

[53]  S. Holgate,et al.  Cellular events in the bronchi in mild asthma and after bronchial provocation. , 1989, The American review of respiratory disease.

[54]  Al-Mayouf Am.  Letter: Protein requirements. , 1974 .